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The Trigger project: the challenge of introducing electronic patient reported 
outcome measures into a radiotherapy service 
Background 
Quality of life is a complex concept spanning multiple domains including physical, mental and 
social well-being. Patient reported outcome measures (PROMS) are tools collected directly 
from the patient and are a valuable method of collecting data on quality of life without the bias 
of the physician (1). PROMs, when used in clinical practice, have been shown to improve 
quality of life for patients and improve overall survival during cancer treatment (1-3). Average 
life expectancy and the number of patients living with and beyond cancer continue to increase, 
however, it is estimated that at least 1 in 4 suffer significant long term side effects following 
their treatment (4, 5). The breadth of choice of treatments are also growing for many patients 
and the decision between treatments with similar survival rates may be best served with good 
quality of life data collected by PROMs. 
The use and publication of PROMs in clinical trials, where there is often dedicated time and 
resource, is poor, and often worse in real-life clinical situation (6). The importance of PROMs 
are starting to be addressed as seen in NHS England’s prioritisation of ‘living with and beyond 
cancer’ with a commitment to roll out a quality of life metric across the country, including 
PROMs questionnaires (7). This will evaluate quality of life in multiple different cancers 
following diagnosis.  
There has been a real difficulty in introducing PROMs data collection in an already over 
stretched NHS service. This is likely to be due to the fact that traditional quality of life 
questionnaires can be long, not well matched to the side effects of particular treatments and 
therefore often considered time consuming and irrelevant to the patient and healthcare 
professional. For successful sustainable uptake of PROMS staff, ‘buy in’ is imperative and so 
far this has often been the main barrier to implementation. 
Project outline 
The Royal College of Radiologists (RCR) and Macmillan Cancer Support were keen to find a 
solution to this problem, combining a useable treatment-specific PROM for radiotherapy 
treatment that could be collected electronically. The electronic collection of the PROM was 
essential to the brief to enable national scale up and reporting. Initially the plan was to scope 
the addition of a PROM to one of the existing national cancer datasets, namely the radiotherapy 
dataset (RTDS), to complement the quality of life metric (8). However following discussion 
with stakeholders this was considered unachievable in this project’s time frame, as the process 
to change a nationally mandated dataset takes 18 months or longer. More importantly, it would 
also change the fundamental way in which the radiotherapy dataset collated its data which was 
directly from radiotherapy machines.  
The original concept evolved to create an electronic method of collection that would be 
independent of national registries but could supply the registries with data if the project 
successfully grew to encompass most of the country. In order to implement this project, the 
system had to be independent of any hospital electronic system, which typically vary. For the 
system to be successfully rolled out it had to be easy to use, set up and relevant to staff (9). It 
would be patient facing to allow patients to input their own data and to gain appropriate consent 
for the use of their data. 
Most importantly the project needed a short treatment specific questionnaire that would take 
minimal time to fill out, but highlight those who needed specific help following treatment. 
ALERT-B is a 4 point questionnaire used to screen for long term bowel toxicity following 
radiotherapy. It is a set of questions validated against traditional PROMs tools (10). Long term 
bowel toxicity is improving following modern radiotherapy techniques however still affects 
quality of life in a significant proportion of people (11, 12). These symptoms are commonly 
not initially attributed by patients to being related to radiotherapy, and clinicians often have a 
poor understanding of the complex effect radiation has on bowel function. Many of the 
symptoms can improve dramatically and rapidly with the correct treatment, but too often these 
patients do not receive the most appropriate care in a timely manner. A key feature of the 
ALERT-B questionnaire, is that the patients who are identified as being in need, can more 
rapidly proceed to being treated according to evidence based treatment protocols that should 
improve their symptoms and quality of life (13).  
The new Radiotherapy Service Specification, which covers the provision of radiotherapy for 
adults in England, suggests that radiotherapy networks  include ALERT-B as a method of 
collecting long term bowel toxicity data (14). This could be a model for other trigger 
questionnaires collected electronically for other tumour groups in the future. 
 
 
Figure 1: ALERT-B screening tool (10) 
A challenge to this project was our limited financial resources to demonstrate that this could 
be achieved at scale as a service evaluation project in multiple centres. Recruitment would have 
to be integrated into normal practice in radiotherapy departments. The model would be based 
around on-treat radiographers who would discuss the service with the patient at the time of 
radiotherapy. The patient would register for the website during radiotherapy and complete the 
questionnaire to record initial acute toxicity. The system would then invite the participant to 
redo the questionnaire 6 months later to collect long term bowel side effects. The major benefit 
to patients of this project is that it picks up early symptoms that may be related to Pelvic 
Radiation Disease and gives patients a contact to call so that they can be linked to the most 
appropriate clinicians to deal with their symptoms. 
Imperial College Healthcare NHS Trust, Brighton and Sussex University Hospitals NHS Trust 
and Velindre University NHS Trust were chosen to give a diverse spread of sites, with a lead 
clinician and radiographer at each department and administration support at Imperial. The aim 
of this 1-year project was to see how many patients registered and then went on to complete 
the 6-month questionnaire, against the denominator of those receiving radical pelvic 
radiotherapy at that particular centre. 
The experience so far 
At the six- month mark of this year-long feasibility project, approximately 250 patients have 
registered with the Trigger Project using an electronic platform hosted by My Clinical 
Outcomes (15). Of those that have answered the initial questionnaires 55% had answered ‘yes’ 
to one or more of the ALERT-B questions which likely represents acute gastrointestinal  
toxicity. We are now beginning to see the return of the six-month post-radiotherapy 
questionnaires. This will give us a tangible measure of the burden of long-term side-effects 
actually experienced by patients receiving pelvic radiotherapy. It may also allow further 
correlation of tumour type with side-effect burden, as all patients receiving pelvic radiotherapy 
are eligible.  
The 248 patients currently registered with the trigger represent, as of January 2019, 12% of the 
eligible patients at Brighton & Sussex, 26% at Imperial, and 39% at Velindre. We are hoping 
to reach the 60% sign up of eligible patients.  
 
Figure 2: Recruitment over time across the three centres 
 
Figure 3: Rates of patients registered on the platform by cancer type 
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The registration level so far has been low and demonstrates the challenges to implement a 
project like this without designated resource in the NHS. There is considerable variability 
between the three sites. This variability has also been found in the NHS England Quality of 
Life Metric pilot study. We continue to use a learning in practice approach through surveys of 
staff and by speaking to sites directly. The higher levels within Velindre could be predicted 
due to their specialist interest in Pelvic Radiation Disease for more than 5 years and thus 
represents a greater degree of change in the other two sites (16). Staff shortages are seen across 
the NHS and this means that already over stretched staff do not have time to take on the extra 
effort required for the TRIGGER project. This may be evident in Brighton and Imperial who 
have a smaller team of on treat radiographers/ nurses. 
This system is designed to help those patients significantly affected by Pelvic Radiation 
Disease after 6 months and point them to the right help more effectively and quickly. Therefore, 
patients may not sign up as they do not see the relevance of the project at the time of 
registration. A lesson to the project is how we can build the system to give more perceived 
benefits for the patient at registration. 
We continue to implement measures to try and combat some of the issues and raise awareness 
to all staff. Examples of these are a promotional video: filmed at the RCR and at all three 
radiotherapy centres to promote patient and staff engagement with the project. Also a monthly 
newsletter: including sign-up rates with a breakdown of cancer type and highlight effective 
practice, aiming to inform clinicians and promote further engagement.  
If these initiatives are effective then this project will have been one of the first of its kind to 
implement the routine collection of entirely-electronic PROMs, in a scalable fashion, without 
dedicated funding for sites. This could significantly improve the experience of patients 
undergoing treatment in the future, as clinical care could support greater self-management and 
improve follow up of oncology patients by remotely identifying problems so that clinicians 
review only those with appropriate need.  
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